Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Tsha save search
Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome
Published: 2023-07-31 (Crawled : 12:00) - globenewswire.com
TSHA | $2.355 -6.92% -7.43% 790K
|
Health Technology
|
| O: 1.77%
H: 4.35%
C: -2.43%
reveal positive trial rett syndrome
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
TSHA | $2.355 -6.92% -7.43% 790K
|
Health Technology
|
| O: 3.62%
H: 8.2%
C: 6.85%
tsha-120 gene therapies report positive gene therapy
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101
Published: 2022-01-27 (Crawled : 12:30) - biospace.com/
TSHA | $2.355 -6.92% -7.43% 790K
|
Health Technology
|
| O: 2.88%
H: 1.27%
C: -13.34%
tsha-101 gene therapies positive gene therapy therapy biomarkers tsha-102
Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design
Published: 2021-12-22 (Crawled : 12:30) - biospace.com/
TSHA | $2.355 -6.92% -7.43% 790K
|
Health Technology
|
| O: -0.59%
H: 1.04%
C: -2.01%
disease gene therapies positive gene therapy designation
Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency
Published: 2021-12-06 (Crawled : 23:00) - biospace.com/
TSHA | $2.355 -6.92% -7.43% 790K
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: 0.0%
treatment presentation preclinical gene therapies potential positive gene therapy pre-clinical
Taysha Gene Therapies Announces Publication of Positive Proof-of-Concept Preclinical Data for an AAV-mediated UBE3A Gene Replacement
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
TSHA | $2.355 -6.92% -7.43% 790K
|
Health Technology
|
| O: -3.46%
H: 4.94%
C: 1.27%
media gene therapies positive preclinical gene therapy therapy pre-clinical
Taysha Gene Therapies Announces Publication of Positive Preclinical Data for TSHA-104 Demonstrating Therapeutic Potential in SURF1-associated Leigh Syndrome in Journal Molecular Therapy: Methods & Clinical Development
Published: 2021-09-15 (Crawled : 12:00) - biospace.com/
TSHA | $2.355 -6.92% -7.43% 790K
|
Health Technology
|
| O: 0.15%
H: 5.48%
C: 4.5%
gene therapies potential positive therapy molecular gene therapy preclinical syndros pre-clinical tsha-102
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.